KARACHI- A new generation of Basal Insulin (Insulin glargine U300) has recently been introduced in Pakistan, by the help and expertise of Sanofi, Pakistan.
This basal insulin has been approved by the FDA in 2015 and since then, it has been used in many countries, including the United States of America, Canada, Russia, Japan and India.
Numerous diabetic patients under treatment fail to reach their blood sugar level goals. However, this new Basal Insulin is designed to act within 24 hours, improving blood sugar levels in diabetic adults.
Sanofi’s insulin glargine U300 works like the human body’s natural insulin and helps control blood sugar levels, when combined with diet and exercise. This new form of insulin promises stable blood sugar levels throughout day and night, offering dosage flexibility.
Country Chair and General Manager, Sanofi Pakistan, Asim Jamal, discussed Sanofi’s century-long heritage in diabetes research and development, empowering diabetics to manage their condition efficiently. He expressed his commitment towards bringing advanced therapies to Pakistan.
Basal Insulin is being manufactured at Sanofi’s ‘Insulin City’ in Germany; and is now available all across Pakistan on prescription.
International experts shared their experiences on management for Diabetes, addressing topics that would help local clinicians to make well informed decisions to facilitate recovery.
Prof. Dr Leszek Czupryniak, Professor at the Department of Diabetology and Internal Medicine, Medical University of Warsaw, Poland stated that; “50% of people living with diabetes remain uncontrolled.”Insulin glargine U300 will help physicians in managing their diabetic patients, whilst drastically reducing the risk of hypoglycemia and keeping their blood glucose levels in balance.